Application of Health Technology Assessment and Pharmacoeconomics in the Decision-Making Process in Selected Eu Member States

Marusakova, E; Bielik, J

doi:10.1016/j.jval.2013.08.1994

Value in Health

2013

DOI: 10.1016/j.jval.2013.08.1994

|View full text |Cite

Application of Health Technology Assessment and Pharmacoeconomics in the Decision-Making Process in Selected Eu Member States

E Marusakova¹,

J Bielik

Abstract: A679cos. ConClusiones: Es factible implementar los IMA en 48-72 hs, para responder a consultas puntuales acotadas. El perfil fue diferente al de los informes de ETS tradicionales. Los IMA más solicitados fueron aquellos relacionados con tecnologías terapéuticas, siendo el área oncológica la más frecuente.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Health technology assessment in middle-income countries: recommendations for a balanced assessment system

Dankó

2014

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Because of significant differences in institutional contexts, health technology assessment (HTA) systems that are in place in core pharmaceutical markets may not be suitable, fully or in part, for middle-income countries (MICs) and for other noncore markets. Particular challenges may arise when systems based on the economic evaluation paradigm are conceptualized and implemented in MICs, sometimes with an insufficient level of awareness of the local institutional factors that influence pricing and reimbursement decision making. Focusing on pharmaceuticals, this article investigates possible development directions for HTA systems in MICs and noncore markets bearing similar institutional characteristics, and it provides recommendations for a balanced assessment system (BAS). For this, the main paradigms of HTA have also been reviewed briefly and factors influencing HTA and pricing and reimbursement decisions in MICs and in similar noncore countries have been summarized. The proposed BAS framework takes into account available resources and capabilities and is supposed to facilitate access to new pharmaceuticals while ensuring the transparency of decision-making processes and the stability of the pharmaceutical budget.

show abstract

Health technology assessment in middle-income countries: recommendations for a balanced assessment system

Dankó

2014

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Application of Health Technology Assessment and Pharmacoeconomics in the Decision-Making Process in Selected Eu Member States

Cited by 1 publication

References 7 publications

Health technology assessment in middle-income countries: recommendations for a balanced assessment system

Health technology assessment in middle-income countries: recommendations for a balanced assessment system

Contact Info

Product

Resources

About